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Table 1. LD between SERPINE2 SNPs Expressed as r2
SNP
r2 for SNP
rs1438831 rs920251 rs6747096a rs3795879
rs920251 .952 (1.0) … … …
rs6747096a .140 .148 … …
rs3795879a .140 (.145) .145 (.145) .964 …
ss49785625a .020 .023 .054 .055
NOTE.—The r2 values in parentheses are values obtained from HapMap
and compared with our own data in controls. ss49785625 and rs6747096
are not in HapMap.
a SNP reported by DeMeo et al.1 to be associated with disease in both
family and case-control cohorts.
for the family-based samples. Similarly for rs498055, the
difference in frequencies between the cases and controls
is greater for the unrelated samples than for the linkage
families (table 1). Thus, the failure of Bertram et al. to
replicate our results does not necessarily indicate that the
original association was a false-positive result. We concur
with Bertram et al. that the significant association of
rs498055 in four of six samples “may be unlikely to occur
by chance”1(p181) (in this issue). However, it is possible that
our initial study provided an overestimate of the allelic
OR for rs498055. If this were true and the OR were !1.3,
then the study by Bertram et al. would clearly be under-
powered. Further replication in well-characterized sample
sets is required to assess whether the association is gen-
uine. Ideally, this should be done with large case-control
sample sets, to achieve maximum power. For this partic-
ular marker, we estimate that 360 cases and 360 controls
are needed to achieve 80% power in a replication study
(one-sided ), assuming an allelic OR of 1.3 andap .05
a risk-allele frequency of 45.6%. A meta-analysis of all
studies should then be performed to determine whether
rs498055 is associated with late-onset AD. In addition, it
might be interesting to test the other reported significant
markers from this region in additional sample sets.
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The SERPINE2 Gene and Chronic Obstructive
Pulmonary Disease
To the Editor: In the February 2006 issue of the Journal,
DeMeo et al.1 identified SERPINE2 as a positional candi-
date gene for susceptibility to chronic obstructive pul-
monary disease (COPD [MIM 606963]) and reported on
the association of polymorphic variants of this gene with
early-onset disease in a family-based study andwith severe
disease in a case-control study. With early prior infor-
mation provided by the authors, we have independently
tested for an association of the SERPINE2 gene with COPD
in the largest case-control study reported to date. Our
study consists of 1,018 COPD cases and 911 controls pro-
spectively recruited from six European centers. We have
provided details about the patients elsewhere.2 The study
population was screened for genotypes at the Medical Re-
search Council (United Kingdom) Gene Services Unit for
five SNPs (table 1) in the SERPINE2 gene. All the SNPs
evaluated were reported in the study by DeMeo et al. as
associated with disease, with three of the five associated
with disease in both the family and case-control study
cohorts they assessed.
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Table 2. SERPINE2 Genotype and Allele
Frequencies in Controls and COPD Cases
SNP and
Sample
Frequency
of Allele
Frequency
of Genotype
C T CC CT TT
rs1438831:
COPD case .66 .34 .43 .45 .12
Control .66 .34 .43 .46 .11
A G AA AG GG
rs920251:
COPD case .35 .65 .13 .45 .42
Control .35 .65 .12 .46 .42
A G AA AG GG
rs6747096:
COPD case .79 .21 .61 .35 .04
Control .79 .21 .63 .33 .04
C T CC CT TT
rs3795879:
COPD case .78 .22 .60 .36 .05
Control .79 .21 .62 .33 .05
A G AA AG GG
ss49785625:
COPD case .54 .46 .30 .48 .22
Control .53 .47 .29 .48 .23
We examined linkage disequilibrium (LD) between the
SNPs (table 1) and evaluated SNP and haplotype associa-
tions as described elsewhere.2 DeMeo et al. did not report
specific LD values between SNPs or noncontiguous SNPs
contributing to haplotypes. SNPs and genotype frequen-
cies in the study population are shown in table 2. We
found no significant deviation fromHardy-Weinberg equi-
librium in frequencies for any of the SNPs.
We found no association between any of the SERPINE2
SNPs and disease, in examining both the allelic and ge-
notype distributions, although our study was well pow-
ered to detect associations of the magnitude observed by
DeMeo et al., and we would have expected to see these
frequency differences with the SNPs that we studied. We
also failed to find a relationship between any haplotypes
of these SNPs and disease (data not shown). It was of in-
terest that the allele and genotype frequencies observed
in our control and patient groups were virtually identical
to those observed in control subjects by DeMeo et al.,
indicating a common distribution of SERPINE2 variants
in the European and North American populations studied.
Our previous study has also shown that there is no evi-
dence of population stratification in our sample.
Patients evaluated in both the family-based and case-
control studies reported by DeMeo et al. represent a severe
subset of the disease spectrum. To determine whether the
association with SERPINE2 noted by DeMeo et al. was re-
lated to disease severity, we also analyzed SNP allele and
genotype frequencies in the subgroup of our patients with
forced expiratory volume at 1 s 45% ( ), a groupnp 388
that represents severe disease, but we failed to observe any
association.
Our inability to replicate the observations of DeMeo et
al. in a more highly powered case-control study may be
related to differences in the disease phenotype of the pa-
tients studied, because our patients included those with
and without emphysema. The possibility, however, that
the associations reported by DeMeo et al. represent false-
positive results must also be considered. In this respect, it
is of note that, in the study by DeMeo et al., different
associations were reported for SNPs that are in linkage
disequilibrium with one another. For example, rs3795879
and rs3795877 have an r2 value of 1 in HapMap, yet
different associations with quantitative spirometric phe-
notypes were reported for the family study. Similarly,
rs1438831 and rs920251 are in complete LD, with an r2
value of 1 in HapMap and 0.95 in our study; however, in
DeMeo et al.’s case-control study, the allele and genotype
frequencies of rs920251 were found to be significantly as-
sociated with disease (P values of 0.015 and 0.011, re-
spectively), whereas no similar association was observed
for rs1438831. In both instances, the almost complete
linkage between these pairs of SNPs would be expected to
result in similar associations.
These results underline the importance of replication in
other large independent studies before SERPINE2 can be
unequivocally assigned as a candidate gene for COPD. It
is becoming apparent that, to detectmodest genetic effects
for complex diseases, several independent studies may be
required and the data may need to be subjected to meta-
analysis. For example, this approach has been used to
study Alzheimer disease (see Alzheimer’s AssociationWeb
site). Similar approaches need to be adopted for COPD. It
would also be helpful to have similar criteria adapted for
phenotypic selection and to plan prospective studies on
this basis.
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Reply to Chappell et al.
To The Editor: We appreciate the efforts of Chappell and
colleagues1 to replicate our SERPINE2 findings. We iden-
tified SERPINE2 as a candidate gene for chronic obstructive
pulmonary disease (COPD [MIM 606963]) on the basis of
our gene-expression results (in both murine and human
lung) and our genetic association analysis results in two
study populations. Chappell et al. found no evidence for
association of five SERPINE2 SNPswithCOPD in their case-
control study. As in many complex-disease genetic asso-
ciation studies in general, and in previous COPD ge-
netic association studies in particular,2 the results are
inconsistent.
There are many potential explanations for these incon-
sistent results, including population stratification, genetic
heterogeneity, false-positive and/or false-negative results,
differences in the number of SNPs genotyped, and phe-
notypic heterogeneity.3 In comparing the results of our
two research groups for association analysis of SERPINE2
SNPs with COPD, phenotypic heterogeneity is of partic-
ular importance. COPD is a syndrome composed of both
emphysema and airway disease, with variable contribu-
tions of these processes in different individuals with
COPD. Review of chest CT scans of probands from the
Boston Early-Onset COPD Study—the population in
which we performed family-based association analysis of
COPD-related phenotypes—revealed that the vast major-
ity of these probands had emphysema.4 Moreover, the
COPD cases in our case-control replication population
were clearly selected for emphysema as part of the Na-
tional Emphysema Treatment Trial (NETT). In addition,
the Boston Early-Onset COPD Study probands and the
NETT cases had very severe COPD. Thus, our test and
replication populations were severely affectedwithCOPD,
typically with a substantial degree of emphysema. As
noted by Chappell et al., our cases represent “a severe
subset of the disease spectrum,”1(p185) and their cases rep-
resent a broader spectrum of severity, including individ-
uals with and without emphysema. The differences in
disease severity and emphysema may be important con-
tributors to their nonreplication of our association find-
ings. Also of note, although Chappell et al. genotyped five
SNPs in SERPINE2, they did not genotype several other
SNPs for which we observed replicated associations and
LOD score reduction in conditional linkage models.
Chappell et al. also comment about apparently incon-
sistent association results in our family-based and case-
control association analyses among SNPs in tight linkage
disequilibrium (LD). Modest differences in the statistical
significance of the association analysis results were noted
for several SNPs that are in strong but not complete LD
in our study populations. There are reasonable explana-
tions for these modest differences. (1) The SNP pairs men-
tioned are not in complete LD; in our combined case-
control cohort, the r2 values were 0.93 for rs3795879 and
rs3795877 and 0.91 for rs1438831 and rs920251. (2) De-
spite excellent genotype completion rates, there were
slight differences in missing data between these SNP pairs.
Of note, these were not the only SERPINE2 SNPs signifi-
cantly associated with COPD-related phenotypes in our
study; we observed 18 significantly associated SERPINE2
SNPs in the family-based association analysis and 7 sig-
nificantly associated SNPs in the case-control analysis.
We fully agree with Chappell et al. that replication of
significant associations is essential—which is why we in-
cluded in our article the replication of our family-based
association analysis results in a separate case-control
study. This is also the reason why we provided early access
to significantly associated SNPs to the Chappell and Kal-
sheker group.
Is SERPINE2 a confirmed COPD susceptibility gene? Cer-
tainly not. Before the impact of SERPINE2 on COPD sus-
ceptibility is fully known,more genetic association studies
as well as functional studies will be needed. However, we
contend that SERPINE2 remains a valid COPD candidate
gene. Finally, we agree with Chappell et al. that agreement
on phenotypic definitions and collaboration between re-
